Targeting estrogen responsive elements (EREs): Design of potent transactivators for ERE-containing genes

Molecular and Cellular Endocrinology

Volumn 218, Issue 1-2, 2004, Pages 65-78

  Huang, Jing ^a   Li, Xiaodong ^a   Yi, Ping ^a,b   Hilf, Russell ^a   Bambara, Robert A ^a   Muyan, Mesut ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Designer transregulators; Estrogen; Estrogen receptor; Estrogen responsive genes; Transcription

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; MONOMER; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; BIOENGINEERING; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIMERIZATION; DNA BINDING; ESTROGEN RESPONSIVE ELEMENT; GENE; GENE CONTROL; GENE TARGETING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; LIGAND BINDING; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN TARGETING;

ANIMALS; CELL CYCLE; CELL LINE; DNA-BINDING PROTEINS; ESTROGENS; GENES, REPORTER; PROMOTER REGIONS (GENETICS); RECEPTORS, ESTROGEN; RESPONSE ELEMENTS; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 2342453879     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2003.12.005     Document Type: Article

References (74)

1. Ali S., Metzger D., Bornert J.M., Chambon P. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J. 12:1993;1153-1160
2. Angel P., Baumann I., Stein B., Delius H., Rahmsdorf H.J., Herrlich P. 12-O-Tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5′-flanking region. Mol. Cell. Biol. 7:1987;2256-2266
3. Aronica S.M., Katzenellenbogen B.S. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol. Endocrinol. 7:1993;743-752
4. Benten W.P., Stephan C., Lieberherr M., Wunderlich F. Estradiol signaling via sequestrable surface receptors. Endocrinology. 142:2001;1669-1677
5. Brand N.J., Petkovich M., Chambon P. Characterization of a functional promoter for the human retinoic acid receptor-α (hRAR-α). Nucleic Acids Res. 18:1990;6799-6806
6. Charpentier A.H., Bednarek A.K., Daniel R.L., Hawkins K.A., Laflin K.J., Gaddis S., MacLeod M.C., Aldaz C.M. Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Res. 60:2000;5977-5983
7. Chen Z., Yuhanna I.S., Galcheva-Gargova Z., Karas R.H., Mendelsohn M.E., Shaul P.W. Estrogen receptor α mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J. Clin. Invest. 103:1999;401-406
8. Clarke R., Skaar T.C., Bouker K.B., Davis N., Lee Y.R., Welch J.N., Leonessa F. Molecular and pharmacological aspects of anti-estrogen resistance. J. Steroid. Biochem. Mol. Biol. 76:2001;71-84
9. Cress W.D., Triezenberg S.J. Critical structural elements of the VP16 transcriptional activation domain. Science. 251:1991;87-90
10. Elliston J.F., Tsai S.Y., O'Malley B.W., Tsai M.J. Superactive estrogen receptors. Potent activators of gene expression. J. Biol. Chem. 265:1990;11517-11521
11. Foster J.S., Henley D.C., Ahamed S., Wimalasena J. Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol. Metab. 12:2001;320-327
12. Freedman L.P. Anatomy of the steroid receptor zinc finger region. Endocr. Rev. 13:1992;129-145
13. Fuqua S.A., Chamness G.C., McGuire W.L. Estrogen receptor mutations in breast cancer. J. Cell. Biochem. 51:1993;135-139
14. Garcia M., Derocq D., Freiss G., Rochefort H. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc. Natl. Acad. Sci. U.S.A. 89:1992;11538-11542
15. Gerritsen M.E., Williams A.J., Neish A.S., Moore S., Shi Y., Collins T. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc. Natl. Acad. Sci. U.S.A. 94:1997;2927-2932
16. Glass C.K. Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. Endocr. Rev. 15:1994;391-407
17. Green S., Kumar V., Krust A., Walter P., Chambon P. Structural and functional domains of the estrogen receptor. Cold Spring Harb. Symp. Quant. Biol. 51:1986;751-758
18. Gruvberger S., Ringner M., Chen Y., Panavally S., Saal L.H., Borg A., Ferno M., Peterson C., Meltzer P.S. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 61:2001;5979-5984
19. Hall J.M., Couse J.F., Korach K.S. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J. Biol. Chem. 276:2001;36869-36872
20. Hayes J.J., Tullius T.D. The missing nucleoside experiment: a new technique to study recognition of DNA by protein. Biochemistry. 28:1989;9521-9527
21. Ince B.A., Zhuang Y., Wrenn C.K., Shapiro D.J., Katzenellenbogen B.S. Powerful dominant negative mutants of the human estrogen receptor. J. Biol. Chem. 268:1993;14026-14032
22. Inoue A., Yoshida N., Omoto Y., Oguchi S., Yamori T., Kiyama R., Hayashi S. Development of cDNA microarray for expression profiling of estrogen-responsive genes. J. Mol. Endocrinol. 29:2002;175-192
23. Jordan V.C., Morrow M. Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr. Rev. 20:1999;253-278
24. Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchiyama S., Sasaki H., Masushige S., Gotoh Y., Nishida E., Kawashima H., Metzger D., Chambon P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270:1995;1491-1494
25. Klinge C.M. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 29:2001;2905-2919
26. Klinge C.M., Bodenner D.L., Desai D., Niles R.M., Traish A.M. Binding of type II nuclear receptors and estrogen receptor to full and half-site estrogen response elements in vitro. Nucleic Acids Res. 25:1997;1903-1912
27. Kumar V., Chambon P. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell. 55:1988;145-156
28. Kumar V., Green S., Stack G., Berry M., Jin J.R., Chambon P. Functional domains of the human estrogen receptor. Cell. 51:1987;941-951
29. Kuntz M.A., Shapiro D.J. Dimerizing the estrogen receptor DNA-binding domain enhances binding to estrogen response elements. J. Biol. Chem. 272:1997;27949-279456
30. Kushner P.J., Agard D.A., Greene G.L., Scanlan T.S., Shiau A.K., Uht R.M., Webb P. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74:2000;311-317
31. Lazennec G., Alcorn J.L., Katzenellenbogen B.S. Adenovirus-mediated delivery of a dominant negative estrogen receptor gene abrogates estrogen-stimulated gene expression and breast cancer cell proliferation. Mol. Endocrinol. 13:1999;969-980
32. Lazennec G., Bresson D., Lucas A., Chauveau C., Vignon F. ERβ inhibits proliferation and invasion of breast cancer cells. Endocrinology. 142:2001;4120-4130
33. Lazennec G., Katzenellenbogen B.S. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells. Mol. Cell. Endocrinol. 149:1999;93-105
34. Levenson A.S., Jordan V.C. Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines. J. Steroid. Biochem. Mol. Biol. 51:1994;229-239
35. Luisi B.F., Schwabe J.W., Freedman L.P. The steroid/nuclear receptors: from three-dimensional structure to complex function. Vit. Horm. 49:1994;1-47
36. Ma Z.Q., Tsai M.J., Tsai S.Y. Suppression of gene expression by tethering KRAB domain to promoter of ER target genes. J. Steroid Biochem. Mol. Biol. 69:1999;155-163
37. Mader S., Chambon P., White J.H. Defining a minimal estrogen receptor DNA-binding domain. Nucleic Acids Res. 21:1993;1125-1132
38. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., Evans R.M. The nuclear receptor superfamily: the second decade. Cell. 83:1995;835-839
39. McDonnell D.P. The molecular pharmacology of SERMs. Trends Endocrinol. Metab. 10:1999;301-311
40. Moore P.A., Ruben S.M., Rosen C.A. Conservation of transcriptional activation functions of the NF-kappa B p50 and p65 subunits in mammalian cells and Saccharomyces cerevisiae. Mol. Cell Biol. 13:1993;1666-1674
41. Mosselman S., Polman J., Dijkema R. ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett. 392:1996;49-53
42. Muyan M., Yi P., Sathya G., Willmert L.J., Driscoll M.D., Hilf R., Bambara R.A. Fusion estrogen receptor proteins: toward the development of receptor- based agonists and antagonists. Mol. Cell. Endocrinol. 182:2001;249-263
43. Nardulli A.M., Lew D., Erijman L., Shapiro D.J. Purified estrogen receptor DNA-binding domain expressed in E. coli activates transcription of an estrogen-responsive promoter in cultured cells. J. Biol. Chem. 266:1991;24070-24076
44. Nilsson S., Makela S., Treuter E., Tujague M., Thomsen J., Andersson G., Enmark E., Pettersson K., Warner M., Gustafsson J.A. Mechanisms of estrogen action. Physiol. Rev. 81:2001;1535-1565
45. Nunez A.M., Berry M., Imler J.L., Chambon P. The 5′ flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein. EMBO J. 8:1989;823-829
46. Osborne C.K., Boldt D.H., Estrada P. Human breast cancer cell cycle synchronization by estrogens and anti-estrogens in culture. Cancer Res. 44:1984;1433-1439
47. Parker M.G. Transcriptional activation by oestrogen receptors. Biochem. Soc. Symp. 63:1998;45-50
48. Picard D., Kumar V., Chambon P., Yamamoto K.R. Signal transduction by steroid hormones: nuclear localization is differentially regulated in estrogen and glucocorticoid receptors. Cell Regulat. 1:1990;291-299
49. Rachez C., Lemon B.D., Suldan Z., Bromleigh V., Gamble M., Naar A.M., Erdjument-Bromage H., Tempst P., Freedman L.P. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature. 398:1999;824-828
50. Razandi M., Pedram A., Levin E.R. Plasma membrane estrogen receptors signal to anti-apoptosis in breast cancer. Mol. Endocrinol. 14:2000;1434-1447
51. Regier J.L., Shen F., Triezenberg S.J. Pattern of aromatic and hydrophobic amino acids critical for one of two subdomains of the VP16 transcriptional activator. Proc. Natl. Acad. Sci. U.S.A. 90:1993;883-887
52. Rey J.M., Pujol P., Callier P., Cavailles V., Freiss G., Maudelonde T., Brouillet J.P. Semiquantitative reverse transcription-polymerase chain reaction to evaluate the expression patterns of genes involved in the oestrogen pathway. J. Mol. Endocrinol. 24:2000;433-440
53. Richard S., Zingg H.H. The human oxytocin gene promoter is regulated by estrogens. J. Biol. Chem. 265:1990;6098-6103
54. Russo, J., Hu, Y.F., Yang, X., Russo, I.H., 2000. Developmental, cellular, and molecular basis of human breast cancer. J. Natl. Cancer Inst. Monogr., 17-37.
55. Sadowski I., Ma J., Triezenberg S., Ptashne M. GAL4-VP16 is an unusually potent transcriptional activator. Nature. 335:1988;563-564
56. Safe S. Transcriptional activation of genes by 17β-estradiol through estrogen receptor-Sp1 interactions. Vitam. Horm. 62:2001;231-252
57. Schodin D.J., Zhuang Y., Shapiro D.J., Katzenellenbogen B.S. Analysis of mechanisms that determine dominant negative estrogen receptor effectiveness. J. Biol. Chem. 270:1995;31163-31171
58. Schwabe J.W., Chapman L., Finch J.T., Rhodes D. The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements. Cell. 75:1993;567-578
59. Shang Y., Hu X., DiRenzo J., Lazar M.A., Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 103:2000;843-852
60. Simoncini T., Hafezi-Moghadam A., Brazil D.P., Ley K., Chin W.W., Liao J.K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 407:2000;538-541
61. Soulez M., Parker M.G. Identification of novel oestrogen receptor target genes in human ZR75-1 breast cancer cells by expression profiling. J. Mol. Endocrinol. 27:2001;259-274
62. Stringer K.F., Ingles C.J., Greenblatt J. Direct and selective binding of an acidic transcriptional activation domain to the TATA-box factor TFIID. Nature. 345:1990;783-786
63. Sutherland R.L., Reddel R.R., Green M.D. Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens. Eur. J. Cancer Clin. Oncol. 19:1983;307-318
64. Teng C.T., Liu Y., Yang N., Walmer D., Panella T. Differential molecular mechanism of the estrogen action that regulates lactoferrin gene in human and mouse. Mol. Endocrinol. 6:1992;1969-1981
65. Tora L., White J., Brou C., Tasset D., Webster N., Scheer E., Chambon P. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell. 59:1989;477-487
66. Tremblay A., Tremblay G.B., Labrie F., Giguere V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol. Cell. 3:1999;513-519
67. Triezenberg S.J., Kingsbury R.C., McKnight S.L. Functional dissection of VP16, the trans-activator of herpes simplex virus immediate early gene expression. Genes Dev. 2:1988;718-729
68. Uesugi M., Nyanguile O., Lu H., Levine A.J., Verdine G.L. Induced alpha helix in the VP16 activation domain upon binding to a human TAF. Science. 277:1997;1310-1313
69. Wang M., Dotzlaw H., Fuqua S.A., Murphy L.C. A point mutation in the human estrogen receptor gene is associated with the expression of an abnormal estrogen receptor mRNA containing a 69 novel nucleotide insertion. Breast Cancer Res. Treat. 44:1997a;145-151
70. Wang W., Smith R. 3rd, Burghardt R., Safe S.H. 17β-Estradiol- mediated growth inhibition of MDA-MB-468 cells stably transfected with the estrogen receptor: cell cycle effects. Mol. Cell. Endocrinol. 133:1997b;49-62
71. Wang Y., Miksicek R.J. Identification of a dominant negative form of the human estrogen receptor. Mol. Endocrinol. 5:1991;1707-1715
72. Yi P., Bhagat S., Hilf R., Bambara R.A., Muyan M. Differences in the abilities of estrogen receptors to integrate activation functions are critical for subtype-specific transcriptional responses. Mol. Endocrinol. 16:2002a;1810-1827
73. Yi P., Driscoll M.D., Huang J., Bhagat S., Hilf R., Bambara R.A., Muyan M. The effects of estrogen-responsive element- and ligand-induced structural changes on the recruitment of cofactors and transcriptional responses by ERα and ERβ Mol. Endocrinol. 16:2002b;674-693
74. Zajchowski D.A., Sager R., Webster L. Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. Cancer Res. 53:1993;5004-5011